Neurolase develops advanced technology aimed at enhancing safety and precision during neurosurgery. The company focuses on improving outcomes for brain tumor surgery, which remains the primary treatment modality for these conditions. Their work seeks to transform patient lives by ensuring the initial surgical intervention is as accurate as possible.
Funding
Funding not disclosed
Founders
Product
Problem
Brain tumors are diagnosed in approximately 30,000 individuals annually worldwide, with a projected 47% increase in new cases by 2045. Brain tumors also result in a significant number of years of life lost compared to other cancers. Surgery is the primary treatment modality, making the precision and safety of the initial surgical intervention critical for patient outcomes.
Solution
Neurolase is developing AI-driven technology to enhance safety and precision in neurosurgery, specifically targeting brain tumor removal. Our solutions aim to optimize the effectiveness of these critical first-step surgical procedures. By leveraging advanced computational approaches, Neurolase seeks to improve the precision of surgical interventions and, consequently, transform patient outcomes.
Target Audience
Neurolase's primary customers are neurosurgeons and surgical teams focused on treating brain tumors, as well as medical device manufacturers seeking to integrate advanced AI capabilities into their existing neurosurgical equipment.
Features
- AI-powered image analysis for enhanced surgical planning
- Real-time intraoperative guidance systems
- Predictive modeling for surgical risk assessment
- Integration with existing neurosurgical navigation platforms